ArticleTranslational lung cancer research2025
Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical utility of molecular profiling in rare lung neuroendocrine neoplasms.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Molecular subtyping [Type I (non-small cell lung carcinoma-like, NSCLC-like) and Type II (small cell lung carcinoma-like, SCLC-like)] and YAP1 expression analysis show promise for precision oncology in pulmonary large cell neuroendocrine carcinoma (LCNEC). However, their clinical utility and prognostic value remain unvalidated, and the aim of this study is to evaluate the disparity of clinicopathologic features, survival outcomes and treatment-relevant biomarkers between these two classifications. Methods: We retrospectively analyzed 42 surgically resected pulmonary LCNECs. Using next-generation sequencing (NGS) and immunohistochemistry on archival specimens, we classified tumors by molecular subtype and YAP1 protein expression. Clinicopathological features, survival outcomes, and therapeutic biomarkers were compared between these classifications. Results: Molecular subtyping stratified 61.5% (24/39) as Type I and 38.5% (15/39) as Type II LCNECs. YAP1 immunoreactivity was positive in 71.4% (30/42) of specimens, defining YAP1-negative (n=12) and YAP1-positive (n=30) cohorts. No significant association existed between YAP1 status and molecular subtypes (P=0.15). ASCL1 overexpression (P=0.02) and diffuse prominent nucleoli (P=0.04) were enriched in YAP1-negative tumors, whereas NEUROD1-positive tumors favored YAP1 expression (P=0.04). Type II tumors exhibited elevated POU2F3 expression ( Conclusions: YAP1 expression was independent of molecular subtypes. YAP1-positive tumors may exhibit enhanced responsiveness to immunotherapy/NEUROD1-targeted therapy, while YAP1-negative tumors could benefit from ASCL1/DLL3-targeted approaches. Prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.